SCHEMBL3574625

SCHEMBL3574625

C[Si](C)(C)C#Cc1ccc(OCCN2CCOCC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.57
▸ MAPK1 P28482 2/20 0.57
▸ HRH3 Q9Y5N1 2/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ CHRM2 P08172 1/20 0.57
▸ CHRM1 P11229 1/20 0.57
▸ HTR2A P28223 1/20 0.57
▸ SCN1A P35498 1/20 0.57
▸ HTR2B P41595 1/20 0.57
▸ KCNH2 Q12809 1/20 0.57
▸ SCN2A Q99250 1/20 0.57
▸ SIGMAR1 Q99720 1/20 0.57
▸ SCN3A Q9NY46 1/20 0.57
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ USP2 O75604 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ LTA4H P09960 1/20 0.56
▸ GAA P10253 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322079 0.89 LTA4H (0.56) HRH3CHRM1HTR2ALTA4HKDM4E
SCHEMBL18763470 0.82 CA12 (0.59) ALDH1A1MAPK1HRH3CYP1A2CHRM2
SCHEMBL3566247 0.80 NPC1 (0.62) ALDH1A1MAPK1HRH3CYP1A2CHRM2
SCHEMBL424774 0.80 HRH3 (0.79) ALDH1A1MAPK1HRH3CYP1A2CHRM2
SCHEMBL5214906 0.80 CA12 (0.63) ALDH1A1MAPK1HRH3CYP1A2CHRM2
SCHEMBL82383 0.79 ALDH1A1 (0.67) ALDH1A1MAPK1HRH3CYP1A2CHRM2
SCHEMBL29508217 0.79 ALDH1A1 (0.88) ALDH1A1MAPK1HRH3CYP1A2CHRM2
SCHEMBL21276704 0.79 ACACB (0.53) ALDH1A1MAPK1HRH3CYP1A2CHRM2
SCHEMBL14577989 0.79 NPC1 (0.69) ALDH1A1MAPK1HRH3CYP1A2CHRM2
SCHEMBL3020414 0.77 HRH3 (0.57) ALDH1A1HRH3LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 — — US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 — — US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 — — EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 — — WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 ALDH1A1 869/4885MAPK1 309/4885HRH3 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback